Trial reportArchives of disease in childhood2003
Children with autistic spectrum disorders. II: parents are unable to distinguish secretin from placebo under double-blind conditions.
Trial report in Archives of disease in childhood, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 28 citations in OpenAlex.
- Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study.Nutrients · 2023Trial
- Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin.Archives of disease in childhood · 2003Trial
- Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.Expert opinion on emerging drugs · 2010Review
- Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism.Clinical practice and epidemiology in mental health : CP & EMH · 2005Article
- In children with autism, is intravenous secretin more effective than placebo in improving social skills, communication, behaviour or global functioning?: Part A: Evidence-based answer and summary.Paediatrics & child health · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundStandardised measures of behaviour have failed to detect short term improvement in children with autism following treatment with secretin. However, it is possible that standardised measures are insensitive to dimensions of child behaviour that are nonetheless detectable by parents.
aimTo determine the ability of parents of children with autism to guess, under double blind conditions, whether their child had received secretin or placebo.
methods2x2 crossover randomised blinded study, comparing the effect of synthetic human secretin 2 U/kg to placebo (saline). Sixty two children with autism (aged 43-103 months) were randomly allocated to two groups: group 1 received placebo, followed six weeks later by secretin, and group 2 received secretin followed by placebo. At the conclusion of the study, parents were asked to guess their child's group assignment.
resultsTwenty seven families guessed their child's group assignment correctly and 27 guessed incorrectly. In 48 instances, parents based their guess on perceived improvement; in six cases, parents based their guess on perceived deterioration. Six families saw no difference after either infusion, and offered no guess. One family dropped out after the first infusion, and one family was lost to follow up after the second infusion.
conclusionIn a controlled setting, parents of young children with autism are unable to distinguish the short term behavioural effects of secretin from placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.